FDA Approves Bausch & Lomb Excimer Laser System
ROCHESTER, N.Y., Feb. 27 -- Bausch & Lomb announced that the US Food and Drug Administration has approved the Bausch & Lomb Technolas 217A Excimer Laser System for use in the correction of hyperopia (farsightedness).
With this additional approval, Bausch & Lomb said, the system now offers surgeons a full-treatment range from myopia (nearsightedness) up to -12.00 diopters, with or without astigmatism, to hyperopia up to +4.00 diopters, with or without astigmatism, which would make LASIK surgery available to more patients.
For more information, visit: www.bausch.com
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024